共 66 条
[1]
Siegel RL(2018)Cancer statistics, 2018 CA Cancer J Clin 68 7-30
[2]
Miller KD(2009)Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth Eur Urol 55 310-320
[3]
Jemal A(2002)Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941 J Urol. 168 9-12
[4]
Morgentaler A(1982)Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists Proc Natl Acad Sci USA 79 1658-1662
[5]
Traish AM(1974)Synthetic analogs of luteinizing hormone releasing hormone (LH–RH) substituted in position 6 and 10 Biochem Biophys Res Commun 60 406-413
[6]
Huggins C(1991)Gonadotropin-releasing hormone and its analogues N Engl J Med 324 93-103
[7]
Hodges CV(2006)A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer J Urol. 175 533-536
[8]
Tolis G(2000)Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis Ann Intern Med 132 566-577
[9]
Ackman D(2012)LHRH agonists for the treatment of prostate cancer: 2012 Rev Urol. 14 1-12
[10]
Stellos A(2012)Intermittent androgen suppression for rising PSA level after radiotherapy N Engl J Med 367 895-903